Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) announced that the first U.S. patient has been dosed in COVE-3, the second pivotal clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE